Overview
Yosuke Sugita practices practicing medicine in Tokyo, Japan.
His clinical expertise encompasses Keloids, Postpartum Depression, Pelvic Inflammatory Disease, and Endometritis.
He is actively involved in clinical research, co-authoring 8 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Yosuke Sugita
Is Yosuke Sugita a top-rated expert for Keloids?
MediFind is an objective health platform that identifies experts based on real-world data. Yosuke Sugita is classified as an Experienced expert for Keloids, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Yosuke Sugita participate in research or clinical trials?
Yes. Yosuke Sugita has published 8 articles and abstracts on conditions like Keloids. You can view a list of Yosuke Sugita's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- EndometritisMr. Sugita isExperienced. Learn about Endometritis.
- KeloidsMr. Sugita isExperienced. Learn about Keloids.
- Pelvic Inflammatory DiseaseMr. Sugita isExperienced. Learn about Pelvic Inflammatory Disease.
- Postpartum DepressionMr. Sugita isExperienced. Learn about Postpartum Depression.